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ABSTRACT 
Bacille Calmette-GuBrin (BCG) is the most widely used vac- 
cine worldwide. However, its efficacy varies from 80% to zero 
among studies. Meta-analysis of all the published prospective 
trials and case-control studies indicates approximately 50% 
efficacy against all forms of tuberculosis, but it is even more 
effective against the invasive forms of the disease, meningitis 
and miliaty tuberculosis. Geographic latitude accounts for 41% 
of the variance between studies. The variability between dif- 
ferent BCG preparations and the role of environmental nontu- 
berculous mycobacteria are discussed as major factors in the 
inconsistent results of BCG vaccine trials. New studies to define 
human genes that code for susceptibility to tuberculosis are 
reviewed. Despite the great strides being made in identifying 
vaccine candidates, there is still no reliable surrogate marker 
of protective immunity to tuberculosis. Human efficacy trials to 
document prevention of tuberculosis cannot possibly be 
mounted to test all the vaccine candidates that show promise 
in animal studies. Recent developments discussed include: the 
focus on secreted proteins of Mycobacterium tuberculosis as 
vaccine candidates, the genetic differences between BCG and 
virulent Mycobacterium bovis, the ability to create recombinant 
BCG-expressing cytokines that enhance the immune response 
and express vaccine candidate antigens, the availability of aux- 
atrophic mutants of BCG as vaccine carriers, and the ongoing 
debate about other potential vaccine carriers, such as Salmo- 
nella, vaccinia (particularly modified vaccine Ankara [MVA]) and 
other avirulent pox viruses that do not replicate in humans. 
Key Words: BCG, tuberculosis, vaccine 
Int J Infect Dis 1997; 1:172-178. 
Tuberculosis (TB) has an estimated world prevalence of 
20 million cases. There are 8 million new cases each year, 
and more than 95% of these are in the developing world. 
Whereas in developed countries the vast majority of 
tuberculosis occurs in the age group over 60, in devel- 
oping countries more than 80% of TB cases occur in the 
15 to 59 age group. It is estimated that there are 2 mil- 
lion adult deaths annually from tuberculosis in develop- 
ing countries, more deaths than are caused by any other 
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infectious agent.’ Indeed, this tuberculosis mortality 
accounts for a quarter of all avoidable adult deaths. There 
has been an increase in incidence of tuberculosis since 
the start of the human immunodeficiency virus (HIV) 
epidemic, and in many sub-Saharan countries the num- 
ber of new cases annually has increased 2 to 5 times in 
the last 10 years. It is unclear at this stage whether the 
bulk of these new cases occur as a result of reactivation 
of dormant organisms or by acquisition of new infection 
by an immunocompromised host. Undoubtedly both 
mechanisms occur, and in highly endemic areas where 
the annual risk of infection is high, it is likely that rein- 
fection accounts for a significant proportion of the new 
cases. 
It is striking that over the past 150 years in the United 
Kingdom there has been a steady decline in the mortal- 
ity rate from tuberculosis that cannot be accounted for 
by scientific advances, introduction of BCG immuniza- 
tion, the advent of chemotherapy, or control programs.’ 
There is a significant environmental contribution to the 
susceptibility of individuals to tuberculosis, including 
poverty, crowded housing with many people sleeping in 
one room, and substance abuse, particularly alcohol. 
Those whose immune competence is reduced are also at 
high risk, including those taking immunosuppressive 
agents and steroids, or suffering from malignant disease, 
HIV infection, diabetes, gastrectomy, or achlorhydria. 
Pregnancy, lactation, and old age are also risk factors. 
PUBLIC HEALTH SOLUTION 
Any new effort at introducing a vaccine to replace BCG, 
has to contend with the convincing argument that pub- 
lic health control of tuberculosis is a remarkably cost 
effective intervention. This involves passive case detec- 
tion, sputum microscopy, and short-course chemother- 
apy, which costs less than $10 per discounted year of 
healthy life gained.3 Moreover, in countries where an 
effective tuberculosis control program has been instituted 
(Tanzania, Malawi, Benin, and Vietnam) this package has 
proved remarkably effective, with more than 80% cured 
and less than 3% failures.* It is not surprising that those 
who have to be responsible for national budgets consider 
this an effective package that requires their fmancial back- 
ing, a focused effort, and improved management strate- 
gies. It would be short-sighted, however, to imagine that 
Mycobacterium tuberculosis will be eliminated using 
these public health control program strategies alone. 
172 
Bacterial Vaccines: Tuberculosis / McAdam 173 
Before the advent of chemotherapy, the case fatality 
rate of untreated tuberculosis was about 50%. In 1939, 
the case fatality of smear positive tuberculosis was 44% 
at 1 year, 61% at 3 years, and 66% at 5 years. It is clear, 
therefore, that not everyone dies from this disease and 
that a third or more of those who develop tuberculosis 
self-heal. Although traditional wisdom teaches that those 
who self-heal develop a solid immunity to reinfection, it 
is difficult to find clear evidence for this. Recurrent dis- 
ease has been assumed to be due to reactivation, rather 
than reinfection. The advent of mycobacterial DNA fin- 
ger-printing now allows this question to be answered. In 
developing countries, the standard public health assump- 
tions are that an untreated smear-positive case of tuber- 
culosis infects 20 contacts over 2 years. Only two of these 
20 develop active disease, one of whom will be smear- 
positive.5 Public health efforts focus on the two who 
become infected, but it is clear that the other 90% are 
somehow resistant to tuberculosis. There are many fac- 
tors that account for this resistance, including genetic 
factors and acquired immunity. 
LNCIDENCE OF HIV INFECTION 
Those who are immunocompromised by HIV have an 
increased incidence of tuberculosis, commonly quoted 
at 10% per year in endemic countries, in contrast to a 10% 
lifetime risk in HIV negatives. Antonucci et al found that 
the incidence of tuberculosis in 2695 HIV-infected sub- 
jects in Italy was highest in those who had low CD, 
counts or evidence of advanced HIV disease, or a past his- 
tory of tuberculosis, and those who had a positive skin 
test or who were found to be anergic on skin testing.” 
Again it is notable that not all those whose CD, count 
drops to very low levels develop tuberculosis, even in 
developing countries where the exposure to M. tuber- 
culosis is close to 100%. Those HIV-infected individuals 
who develop tuberculosis tend to have a different spec- 
trum of disease from HIV-negative adults. They are less 
1800s. In the first World War, Senegalese troops died at 
high rates of tuberculosis. More recently, Stead et al have 
shown that Blacks have twice the relative risk of newly 
acquired tuberculosis in nursing homes and prisons in 
Arkansas.8 Crowle and Elkins demonstrated that M. tul?er- 
culosis multiplied faster in the macrophages of Blacks, 
even more so when cultured in autologous plasma, and 
this was reversed by adding vitamin D, in vitro.9 Lurie 
demonstrated genetic resistance to tuberculosis in inbred 
rabbits that were challenged with inhaled M. tuberculo- 
sis.‘O One strain of rabbit developed widely dispersed, 
rapidly progressive disease, whereas another inbred strain 
encapsulated the inhaled organisms in the lung and did 
not develop disseminated disease. He noted that BCG 
protected those with rapid progression more than those 
with better innate resistance. 
Vidal et al have identified a gene that codes for resis- 
tance to intracellular parasites, including BCG, in the 
mouse.‘l This Beg locus also codes for resistance to leish- 
maniasis and Salmonella infection in mice, and it is abro- 
gated by disruption of the Nrampl gene. A human 
homologue has been identified, but so far there is no evi- 
dence that this homologue influences susceptibility to 
mycobacterial infection.l* 
It is perhaps not surprising that people who carry 
mutations in these important immune response genes 
demonstrate variable susceptibility to tuberculosis. 
Indeed, it is likely that there is multigenic control of resis- 
tance to this pathogen. Clearly, development of any new 
vaccine will have to take into account the diversity of 
immune response genes. So far no clear pattern has 
emerged for human leukocyte antigen (HLA)-linked sus- 
ceptibility to tuberculosis. In south India pulmonary 
tuberculosis was associated with HLA-DR2.13 It seems 
unlikely that peptide vaccines would be an effective strat- 
egy against tuberculosis that is likely to require a multi- 
component vaccine to augment a multipronged attack 
against this intracellular organism. 
likely to have apical regions of the lung affected, cavi- 
tating disease, or positive sputum smears, and more likely BACILLE CALMETTE-GUBRIN 
to have lower zones of the lung affected, lymph node 
involvement, and extrapulmonary disease. As the CD, 
count becomes lower, there is less granulomatous 
response noted histologically. Tuberculous meningitis and 
miliary tuberculosis occur more frequently in those with 
lowest CD, counts.’ 
GENETIC SUSCEPTIBILITY TO TUBERCULOSIS 
In addition to acquired immunity, it is evident that there 
are resistance genes that contribute both to the outcome 
of exposure to M. tuberculosis and also to the pattern of 
clinical disease. Early explorers in Africa found no 
evidence of tuberculosis in the interior of Africa in the 
In 1906 oral infection of guinea-pigs with weakly virulent 
equine tubercle bacillus led to persistent infection in 
lymph nodes and conferred resistance to reinfection by 
the intravenous route. A virulent bovine strain had been 
isolated by Nocard from a heifer with tuberculosis mas- 
titis, and after 39 passages, a change in the colony mor- 
phology in culture was noted.‘* Over the next 13 years, 
this avirulent mutant was tested in many species and 
offered protection against tuberculosis without reversion 
to virulence. Vaccine (BCG) was given to 969 children of 
tuberculous mothers orally on days 3, 5, and 7; only 3.9% 
of them died of tuberculosis compared with 32.6% of 
the unimmunized children. The vaccine was introduced 
in 192&l* 
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A disaster occurred in 1929 in Lubeck, Germany, 
where 25 1 children were given BCG prepared locally and 
72 of them died. Investigation revealed that the children 
had inadvertently been given a virulent strain ofM tuber- 
culosis, and although BCG was vindicated, this disaster 
held up widespread implementation of BCG immuniza- 
tion. It is remarkable to consider that not all the children 
died from this disastrous mistake, and 179 did not. It 
would be particularly interesting to reexamine the resis- 
tance factors in those who survived. 
Globally BCG has been given to more people than 
any other vaccine, with an estimated 100 million new- 
borns receiving BCG annually; a total of 3 billion doses 
distributed worldwide is widely quoted.’ There are sev- 
eral advantages of BCG: it can be given at birth as a sin- 
gle inoculum, which produces long-lasting sensitization. 
It is safe, stable, produces a scar, and is inexpensive. Ini- 
tially BCG was given orally, but the organism is killed by 
acid and tended to cause cervical adenopathy when given 
by this route. The World Health Organization recommend 
intradermal administration, since subcutaneous injections 
give a higher incidence of abscesses and lymph- 
adenopathy. Aerosol administration has been shown to 
protect guinea-pigs and has also been given safely to 
human volunteers. There is some evidence to suggest 
that a low dose might be preferable to high doses of BCG, 
because the low doses stimulate a protective T helper 1 
(Thl) type immune response. 
At least 10 control trials of BCG have been con- 
ducted worldwide, demonstrating remarkably variable 
protective efficacy,15 from 77% in British schoolchild- 
ren16 to no effect in the southern United States and in 
the large Chingleput study in south India. The vaccine 
conferred clear benefit against disseminated childhood 
tuberculosis and against tuberculous meningitis (64% 
protection). Regression analysis of BCG efficacy has 
examined the possible effect of various contributing fac- 
tors. Geographic latitude accounted for 41% of the 
between-study variance, according to random effects 
regression analysis of prospective studies.” Possible con- 
tributing factors for this effect of latitude were consid- 
ered, including socioeconomic factors, genetic variables, 
climate, sunlight, diet, virulence of M. tuberculosis 
strains, BCG storage and viability, and the prevalence of 
environmental mycobacteria. Of these various factors, 
two are discussed. 
Vaccine Variability 
The BCG vaccine that is used in different parts of the 
world is not standardized. Indeed it is produced in sev- 
eral different laboratories and has been shown to have 
marked genetic variability, and at times even the cultural 
characteristics, growth rate, morphology, antigen expres- 
sion, and viability have changed. In 1966, three parent 
strains accounted for 90% of the vaccine worldwide 
(Glaxo 1077, Tokyo 172, and Pasteur 1173 P2). To reduce 
the variability, it was suggested that seed lots should be 
frozen and subjected to only 12 passages. The organism 
is grown in liquid culture, which is then homogenized, 
freeze dried, and resuspended. There is a wide variation 
in the number of viable organisms per mass of bacteria, 
such that 10’ bacilli per milligram BCG yield only 5 to 45 
x lo6 colony-forming units. The variability of vaccines 
that are given to children is amplified by the problems 
of storage of BCG. Tropical sunlight for 5 minutes 
reduced viability of BCG by 99%. In contrast, Danish sun- 
light for 5 minutes reduces viability of BCG by less than 
50%. Storage at 37°C for 1 week reduced viability of BCG 
by about 75% as compared with storage at 4°C. 
UNICEF undertakes the purchase of large lots of vac- 
cine from different manufacturers and then distributes it 
worldwide. Often those who administer the vaccine are 
unaware of its origins or of the variable strength of dif- 
ferent types of BCG. During the late 1980s in various 
Central African countries, the supplier of BCG changed 
from Glaxo to Pasteur, leading to an outbreak of axillary 
and cervical lymphadenopathy and abscesses. At the time, 
these events were investigated as a potential complication 
of HIV infection, but no such association was found. 
When the inoculum size of the Pasteur vaccine was 
reduced, the problems disappeared. 
Environmental Mycobacteria 
A second major variable that is always brought up as a 
reason for differences of efficacy of BCG by geographic 
latitude is the prevalence of environmental, nontuber- 
culous mycobacteria. The evidence for this is strong. In 
the 1940s skin tests in 14,000 nurses throughout the 
United States showed large variance in positivity rate, 
between 14% and 70%, the highest frequency being in 
the south-eastern states. Tuberculin skin tests (PPD/B) of 
army recruits for Mycobacterium avium yielded a 33% 
positivity that varied from 20% in the northern states to 
80% in the southern states. Further evidence comes from 
experimental studies in guinea pigs and mice immunized 
with Mycobacterium kansasii, which were 80% as pro- 
tected from M. tubeculosis challenge as with BCG immu- 
nization.” The most compelling data came from one 
million American navy recruits who were skin tested 
with both PPD derived from Mycobacterium bovis 
(PPD/S) and that from M. avium (PPD/B).” The inci- 
dence of tuberculosis between 1958 and 1969 was 49 
per 100,000 for the total population. Those who had a 
strongly positive Mantoux reaction to PPD/S had an inci- 
dence of 382 per 100,000. This incidence was slightly 
lower (273 per 100,000) if they had a smaller PPD/S 
response (6-l 1 mm). However, if they had a larger 
response to the M. avium (PPD/B) skin test antigen than 
to PPD/S the incidence was cut to 29 per 100,000, sim- 
ilar to the level found in PPD/S negative subjects. These 
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data suggest a strongly protective effect of environmen- 
tal mycobacteria against the development of tuberculosis. 
More recently Stanford and Grange have used an iso- 
late of Mycobacterium vuccue derived from a soil sample 
in Uganda as a nontuberculous mycobacterial vaccine.‘9 
They have evidence that killed 34. vaccae induces a 
delayed hypersensitivity reaction without the more 
aggressive necrotic response that can sometimes be 
obtained with BCG. Indeed they have now launched a 
company to make M. mccae under good microbiologic 
practice for use in humans, and a large trial is under way 
in South Africa to test its efficacy at reducing the dura- 
tion of chemotherapy in patients with tuberculosis. 
TUBERCULIN SKIN TEST CONVERSION 
Although BCG is used widely throughout the world, it is 
not used routinely in the United States or in Holland, 
where the incidence of tuberculosis is sufficiently low 
for BCG immunization not to be cost effective. Moreover, 
the administration of BCG complicates the interpretation 
of subsequent Mantoux tests. Thus, in the United States, 
contacts of tuberculosis patients whose Mantoux skin 
tests convert from negative to positive are assumed to 
be infected and are given prophylaxis with isoniazid for 
a year. In contrast, this practice cannot be applied in 
tuberculosis-endemic countries, where Mantoux skin tests 
are positive in up to 80% of the population by the age of 
15. 
Analysis of the results of the Medical Research Coun- 
cil (MRC) trial in Great Britain led Hart and Sutherland 
to conclude that “with highly effective tuberculosis vac- 
cines, the degree of protection conferred on the indi- 
vidual is independent of the degree of tuberculin skin 
test sensitivity induced in that individual by vaccination.” 
Similarly, a trial of BCG in the southern regions of India 
demonstrated little protection from BCG despite good 
vaccine-induced tuberculin conversion. However, it is 
still widely assumed that, because the skin tests of some 
individuals convert to positive after BCG immunization, 
this somehow reflects a surrogate marker of protective 
immunity It is also clear that those who have a strongly 
positive skin test are the ones most likely to develop 
tuberculosis. Thus, the category of individuals who may 
be innately most resistant to infection could be those 
who maintain a negative skin test despite exposure. In 
every group of health care workers who spend a lot of 
time working with patients with tuberculosis there are a 
few who remain skin-test negative despite this occupa- 
tional exposure. 
The whole debate about skin-test conversion and risk 
of tuberculosis has come to a particularly heated debate 
in the United States during the past few years when it is 
claimed that skin tests of the medical house staff looking 
after patients in New York were converting from negative 
to positive at the rate of 10% per year. Moreover a deci- 
sion analysis comparing tuberculin screening strategy 
with BCG vaccination concluded that BCG unequivocally 
leads to fewer cases of tuberculosis over 10 years. More- 
over, BCG requires only an efhcacy rate of 13% to pre- 
vent more cases than current strategy. The conclusion 
was that BCG vaccine should be considered for tuber- 
culin negative house officers and medical students work- 
ing in high risk areas in the United StateszO Although this 
conclusion is hotly debated by other experts, opinions 
remain divided about the value of immunization with 
BCG in a country with low prevalence of disease, such 
as the United States. 
WORK TOWARD A NEW VACCINE TO REPLACE 
BCG 
The variability of different batches of BCG and the dif- 
ferences in protective efficacy associated with the rising 
incidence of tuberculosis throughout the world demand 
a review of current vaccine strategies against tuberculo- 
sis. Within the next couple of years the sequence of the 
entire M. tuberculosis genome will be complete. The 
genomic sequence of every protein produced by the 
organism will be known. It will be possible to screen, in 
recombinant live organisms, a large number of potential 
vaccine candidates for protection in animal studies. 
Unfortunately available animal models do not mirror the 
situation in humans. However, they provide a much more 
realistic method of screening vaccine candidates. This 
task is now under way, mainly using the mouse model. 
However, guinea pigs and rabbits are reasonable alter- 
natives, and the pig is more similar to humans in sus- 
ceptibility and immune responseszl 
The major problem in humans is to define protective 
immunity. Surprisingly this is not yet understood. Surro- 
gate markers of effective immunity are not available, 
although this is a high-priority area for research. Large 
population studies are expensive and take a long time to 
generate data on protective efficacy. It would be impos- 
sible to test every promising vaccine candidate in 
prospective randomized blinded efficacy studies?* The 
definition of surrogate markers of protective immunity is 
now a high priority. 
PROTECTIVE IMMUNITY 
The dogma that a positive skin test to tuberculin reflects 
protective immunity requires further analysis. Those who 
have a negative skin test response are more susceptible 
to tuberculosis than those who have an intermediate 
response. However, there is a U-shaped curve of sus- 
ceptibility,23 with highest susceptibility found in those 
with large Mantoux responses of 15 mm or more. 
176 International Journal of Infectious Diseases / Volume 1, Number 3, January 1997 
Current dogma suggests that an effective immune 
response against M. tuberculosis depends on the stimu- 
lation of the Thl arm of the immune response generat- 
ing interferon y, which stimulates killing of intracellular 
mycobacteria. Anything that deviates the immune 
response toward a Th2 direction would be detrimental.24 
There is evidence that those with HIV infection tend to 
exhibit a Th2 response, as do those with allergies. How- 
ever, there are no data to suggest that atophic individu- 
als are more susceptible to tuberculosis, so this 
hypothesis cannot be entirely sustained. The Thl 
response induces effective granuloma formation, to con- 
tain the bacteria, but this granulomatous response also 
depends on tumor necrosis factor, which causes fever 
and weight loss if produced in excess. 
Cytotoxic T cells may play a critical part in effective 
immunity against tuberculosis. In experimental studies 
knock out animals that have lost genes important for class 
I and class II responses have succumbed to tuberculosis, 
suggesting that both these pathways are important for 
protection. The generation of cytotoxic lymphocyte 
responses requires activation of lymphocytes bearing 
class I major histocompatibility complex molecules of 
the CD, phenotype. To activate these cells, the antigen 
is processed via the endoplasmic reticulum, whereas class 
II activation is generated via degradation of protein in 
the phagolysosome. Whereas BCG tends to remain within 
the phagolysosome and therefore generates mainly class 
II responses, M. tuberculosis is more virulent and escapes 
out of the phagolysosome and into the cytoplasm, 
thereby generating class I responses also. However, this 
is not the whole story, because experimentally, class I 
responses have been found in BCG immunized individu- 
als, suggesting that secreted proteins might escape out of 
the phagolysosome and into the cytoplasm, where they 
stimulate a class I CD, T-cell response. It is assumed that 
such cytotoxic T cells kill infected macrophages and 
release the live mycobacteria, which are then phagocy- 
tosed and killed by freshly recruited macrophages from 
other sites. 
It has long been assumed that antibodies are totally 
ineffective in tuberculous immunity despite being pro- 
duced in large quantities in infected individuals. These 
high antibody concentrations are generated through a 
Th2 response and by polyclonal T-cell independent 
immune responses. Whether antibodies interfere with 
effective killing of organisms or opsonize organisms for 
phagocytosis remains unclear, although there is evidence 
that mycobacteria are internalized through complement 
receptors. 
Antigens of M. tuberculosis 
The most immunogenic antigens in terms of antibody 
responses have been the stress or heat shock proteins, 
produced as part of the stress response induced by 
phagocytosis and internalization. Much attention has been 
paid to these proteins over the past 10 years, and par- 
ticular interest has centered on the stimulation of auto- 
antibodies in response to some of these mycobacterial 
heat shock proteins. Recently, particular interest has cen- 
tered around the 6 kD and 30-32 kD secreted proteins 
of M. tuberculosis and how these differ between BCG 
and virulent M. tubercuZosis.25 
Most pathogens have multiple genes responsible for 
virulence, highlighting the redundancy of different meth- 
ods by which the organism can enter and survive in a 
hostile environment within the host. For instance, the 
Inv A gene from Yersinia pestis has been found to have 
some (17%) homology with a mycobacterial invasin. In 
Salmonella there are at least 30 different proteins rec- 
ognized when cultured in macrophages rather than in 
media alone. 
Mahairas et al have defined the genetic differences 
between M. bovis BCG and virulent M. bovis.26 Using sub- 
tractive genomic hybridization to identify genetic differ- 
ences, they noted three distinct genomic regions. One of 
these, RDl, is a 9.5 kb DNA segment found to be deleted 
from all BCG substrains but conserved in all virulent iso- 
lates of M. bovis and M. tuberculosis tested. The rein- 
troduction of RDI into BCG permitted the expression of 
at least 10 proteins and resulted in a protein expression 
profile almost identical to that of virulent M. bovis. They 
conclude that RDl is involved with regulation of multi- 
ple genetic loci and that the loss of virulence of BCG is 
attributable to a regulatory mutation. This particularly 
interesting definition of the attenuation of BCG offers 
the opportunity to use live BCG for a vaccine carrier. 
Indeed, considerable effort has been made to introduce 
into BCG genes for better protection against tuberculo- 
sis and for augmenting the immune response. Murray et 
al have shown that recombinant BCG strains that secrete 
cytokines are more effective at stimulating immune 
responses against BCG in mice.27 This may be a particu- 
larly promising way of enhancing immune responses to 
mycobacterial antigens. Others have generated aux- 
atrophic variants of BCG.” These live attenuated BCG 
organisms do not survive in immunocompromised ani- 
mals, but protect against virulent M. tuberculosis. This 
may be particularly important when considering the 
immunization of immunodeficient individuals, such as 
the large HIV-infected population at risk of tuberculosis. 
Because live attenuated organisms do not multiply in the 
human host, a safer vaccine is envisaged that can be used 
in HIV-positive individuals. 
Other approaches to vaccine development include 
the production of recombinant attenuated pox viruses 
or Sahnonella vectors into which have been cloned 
immunodominant antigens from mycobacteria that stim- 
ulate CD, and CD, T-cell responses in those immunized. 
Some of the attenuated pox viruses do not multiply 
within the human host and therefore resemble the 
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auxotrophic mutants of BCG. They have the other advan- 
tage of being well-tested in humans over 200 years since 
the introduction of cowpox vaccination by Jenner. The 
Ankara strain of modified vaccinia seems particularly 
promising (Blanchart T, Smith G, et al. Personal commu- 
nication). This approved vaccine stain of vaccinia has 
been safely given to many people during the smallpox 
eradication campaign. Recently it has been shown to lack 
some of the cytokine receptors that confer resistance to 
host immune responses. 
As mentioned previously, atypical mycobacteria are 
protective against tuberculosis, and M. vaccae is currently 
of special interest. Other atypical mycobacteria dso have 
shown protective efficacy against tuberculosis, including 
M. microti, in the British BCG trial,” and Mycobacterium 
F$ in India. 
Horowitz et al have protected animals with a com- 
bination of secreted proteins in a subunit vaccine.29 This 
approach has the advantage that the vaccine is not a live 
vaccine and is less susceptible to environmental variables, 
storage, and growth than a live vaccine. However, it suf- 
fers the disadvantage of genetic variation in immunologic 
responses between different individuals. Once the impor- 
tant antigens for protective immunity have been defined, 
it may be possible to introduced the genes for these anti- 
gens into vaccine carriers that are able to deliver multi- 
ple vaccines within one organism. These so-called multi- 
vaccines offer a particularly attractive prospect. The one- 
time vaccine given at birth or shortly afterward would be 
an enormous advantage from a practical point of view of 
delivery of vaccine in developing countries. 
Perhaps the most exciting development has been the 
use of naked DNA vaccines30 in which DNA is injected 
into muscle and induces the synthesis of relevant vac- 
cine antigens by the host cell. The expressed proteins 
induce a protective immune response, including anti- 
bodies and cellular immune and cytotoxic responses. 
However, there are regulatory concerns about naked DNA 
vaccines that have already been shown to be effective in 
protecting animals against tuberculosis.31 There is the 
unsubstantiated danger that DNA will be randomly 
inserted into the host genome and induce cancers or 
other problems at the site of inoculation. It is unclear 
how these concerns will be allayed. 
TESTING VACCINES 
Perhaps the most challenging future scenario to consider 
is how to test human vaccines, of which there appear to 
be a proliferating number of candidates.32 Surrogate mark- 
ers of protective immunity are required as well as sus- 
ceptible populations with a high incidence of 
tuberculosis in which the most promising candidates can 
be tested in prospective double-blind randomized trials 
of efIIcacy.33 These trials are expensive and require huge 
investments in human resources as well as expertise and 
time to reach conclusions. Consideration of all vaccine 
candidates for phase 3 trials is not affordable, and urgent 
attention needs to be given to the way in which the most 
promising candidates are selected for efficacy trials. 
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